Journal Mobile Options
Table of Contents
Vol. 12, No. 2, 2001
Issue release date: March–April 2001
Dement Geriatr Cogn Disord 2001;12:69–77

APOE Genotype: No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer’s Disease

Aerssens J. · Raeymaekers P. · Lilienfeld S. · Geerts H. · Konings F. · Parys W.
Departments of aPharmacogenomics, bCNS and Analgesia, cLife Sciences, and dDevelopment Operations and Technologies, Janssen Research Foundation, Beerse, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Apolipoprotein E (APOE) has been extensively demonstrated to be a genetic risk factor for Alzheimer’s disease (AD). Associations of APOE genotype have been reported with age at AD onset, rate of decline, and responsiveness to therapy. This study aimed to test these hypotheses in a large study population of AD patients. APOE genotype was determined from 1,528 Caucasian subjects, diagnosed by NINCDS/ADRDA criteria as probable AD patients, enrolled in four international placebo-controlled clinical trials of 3–12 months duration, designed to evaluate efficacy of treatment with galantamine or sabeluzole. In addition to patient demographics and baseline scores for Mini Mental State Examination, scores on the Disability Assessment for Dementia (DAD) and the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were recorded at the start, during, and at the end of the study. APOE ε4 homozygotes had a significantly lower age at disease onset compared to patients with other APOE genotypes. The ε4 allele was significantly over-represented in females compared to males, and in the group of subjects with an AD family history. Based on longitudinal data of 504 placebo-treated AD patients, the linear annual rate of change in score was 5 points on the ADAS-cog scale and 11 on the DAD scale. The ε4 allele copy number did not influence these rates of decline. Sabeluzole treatment was not effective in the overall group compared to the placebo-treated group, nor in any subgroup stratified by ε4 allele count. Galantamine produced cognitive and functional improvement that were not affected by ε4 allele count. In conclusion, our data confirm a strong association between ε4 homozygotes and age at onset of AD but do not support an effect of ε4 allele copy number on rate of cognitive and functional decline nor on the efficacy of galantamine in patients with AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Periack-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  2. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
  3. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Rische N, van Duijn CM, for the APOE and Alzheimer Disease Meta Analysis Consortium: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer’s disease. JAMA 1997;278:1349–1356.
  4. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH, for the Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med 1998;338:506–511.
  5. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang M, Maestre G, Ngai C, Tycko B, Ginsberg H: The apolipoprotein ε4 allele in patients with Alzheimer’s disease. Ann Neurol 1993;34:752–754.
  6. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT: Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease. Neurology 1996;47:444–448.
  7. Kurz A, Egensperger R, Haupt M, Lautenschlager N, Romero B, Graeber MB, Müller U: Apolipoprotein E allele ε4, cognitive decline, and deterioration of everyday performance in Alzheimer’s disease. Neurology 1996;47:440–443.
  8. Murman DL, Foster NL, Kilgore SP, McDonagh CA, Fink JK: Apolipoprotein E and Alzheimer’s disease: strength of association is related to age at onset. Dementia 1996;7:251–255.
  9. Norrman J, Brookes AJ, Yates C, St Clair D: Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer’s disease. Br J Psychiatry 1995;167:533–536.
  10. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, Marder K, Sano M, Albert S, Del-Castillo Castenada C, Bylsma F, Tycko B, Mayeux R: The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer’s disease. Ann Neurol 1997;41:615–620.
  11. Plassman BL, Breitner JCS: Apolipoprotein E and cognitive decline in Alzheimer’s disease. Neurology 1996;47:317–320.
  12. Dal Forno G, Rasmusson DX, Brandt J, Carson KA, Brookmeyer R, Troncoso J, Kawas CH: Apolipoprotein E genotype and rate of decline in probable Alzheimer’s disease. Arch Neurol 1996;53:345–350.
  13. Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, Trabucchi M: Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer’s disease. Ann Neurol 1995;37:596–604.
  14. Murphy GM Jr, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR: No association between apolipoprotein E ε4 allele and rate of decline in Alzheimer’s disease. Am J Psychiatry 1997;154:603–608.
  15. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB: Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer’s disease. Neurology 1998;51:149–153.
  16. Olichney JM, Sabbagh MN, Hofstetter CR, Galasko D, Grundman M, Katzman R, Thal LJ: The impact of apolipoprotein E4 on cause of death in Alzheimer’s disease. Neurology 1997;49:76–81.
  17. Combarros O, Leno C, Oterino A, Berciano J, Fernandez-Luna JL, Fernandez-Viadero C, Pena N, Miro J, Delgado M: Gender effect on apolipoprotein E ε4 allele-associated risk for sporadic Alzheimer’s disease. Acta Neurol Scand 1998;97:68–71.
  18. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993;342:697–699.
  19. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S: Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996;802:101–110.
  20. Richard F, Helbecque N, Neuman E, Guez D, Levy R, Amouyel P: APOE genotyping and response to drug treatment in Alzheimer’s disease. Lancet 1997;349:539.
  21. Folstein, M, Folstein, S, McHugh, P: Mini-mental state. A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  22. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  23. Gauthier L, Gauthier S, McIntyre M, Wood-Dauphinee S: Assessment of functioning and ADL. Abstracts of the Sixth Congress of the International Psychogeriatric Association; September, 1993; Berlin, p 9.
  24. Wendham PR, Price WH, Blundell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  25. Slooter AJC, Cruts M, Kalmijn S, Hofman A, Breteler MMB, Van Broeckhoven C, van Duijn CM: Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol 1998;55:964–968.
  26. Lucotte G, Turpin JC, Landais P: Apolipoprotein E-ε4 allele doses in late onset Alzheimer’s disease. Ann Neurol 1994;4:681–682.
  27. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180–184.
  28. Masullo C, Daniele A, Seripa D, Filippini V, Gravina C, Carbone G, Gainotti G, Fazio VM: Apolipoprotein E genotype in sporadic early- and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:121–125.
  29. Breitner JCS, Silverman JM, Mohs RC, Davis KL: Familial aggregation in Alzheimer’s disease: Comparison of risk among male and female relatives in successive generations. Neurology 1988;38:207–212.
  30. Van Bockxmeer FM, Mamotte CDS: Apolipoprotein ε4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879–880.
  31. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A: ApoE ε4 allele and cognitive decline in patients with Alzheimer’s disease. Neurology 1996;47:603.
  32. National Institute on Aging/Alzheimer’s Association Working Group: Apolipoprotein E genotyping in Alzheimer’s disease. Lancet 1996;274:1627–1629.
  33. Schneider LS, Farlow MR: Predicting response to cholinesterase inhibitors in Alzheimer’s disease. Possible approaches. CNS Drugs 1995;4:114–124.
  34. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260–12264.
  35. Albuquerque E, Alkondon M, Pereira E, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A: Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117–1136.
  36. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr, Davis L, Vargas HM: Pharmacological evaluation of novel Alzheimer’s disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728–738.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50